drugset / Trial / NCT06646354

To Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients With Essential Hypertension and Primary Hypercholesterolemia

NCT06646354

Phase 3 Enrolling by invitation 125 enrolled Hyundai Pharm
RandomizedParallel-groupDouble-blindTreatment

Summary

A Multicenter, Randomized, Double-blind, Active-controlled, Parallel group, Phase 3 trial to Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients with Essential Hypertension and Primary Hypercholesterolemia

Timeline

Start
2025-04-22
Primary completion
2025-05-19
Completion
2028-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amlodipine Other / unclassified Oral
Subject Ezetimibe Unknown Oral
Subject Rosuvastatin Small molecule Oral
Comparator Candesartan Unknown Oral